Metabolic · Investigational
Danuglipron
No lawful US pathway
01 · Overview
Danuglipron (PF-06882961) is an oral, non-peptide small-molecule agonist of the GLP-1 receptor that was developed for type 2 diabetes and obesity (PMID 40539310). It mimics the effects of endogenous GLP-1 by enhancing glucose-dependent insulin secretion, suppressing glucagon, and slowing gastric emptying.
Its small-molecule structure allows oral dosing, given twice daily in clinical studies (PMID 40539310).
02 · Research summary & key findings
In a 12-week phase 2 study in type 2 diabetes, danuglipron lowered HbA1c, fasting glucose, and body weight versus placebo, but discontinuation rates were high, with nausea and vomiting most common (PMID 37311722). In a phase 2b obesity trial, placebo-adjusted weight reductions ranged from 5.0 to 12.9 percent, but only 39 percent of participants completed treatment and about 38 percent stopped because of adverse events (PMID 40539310). Liver toxicity signals were reported during its clinical development (PMID 42418948).
03 · Regulatory status
Danuglipron is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
No lawful pathway today
Danuglipron is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so we do not sell it and will not book a consultation for it. That can change: in 2026 FDA began reviewing several peptides for compounding. If you are working on the goal it is studied for, a licensed clinician can tell you what is lawfully available, which may be something else.
See the 13 FDA-approved compounds in Metabolic
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Looking for a lawful, clinician-prescribed option for metabolic health and weight?
Danuglipron is an investigational compound, is not FDA-approved, and has no lawful US compounding pathway, so we do not offer it and no clinician we work with will prescribe it. Products sold online as “research chemicals” are not made or tested to the standards required of medicines. If you are working on metabolic health and weight, a licensed clinician can tell you at a free consultation whether an FDA-approved or lawfully compounded treatment fits you, or whether nothing does.
Explore lawful options (free intake)About 3 minutes. If a protocol is prescribed through our provider, we earn 10% of the sale. See the receipts.
04 · Administration routes
- Oral
References
- [1]Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes Diabetes Obes Metab, 2023. PMID 37311722
- [2]Efficacy and safety of danuglipron (PF-06882961) in adults with obesity: A randomized, placebo-controlled, dose-ranging phase 2b study Diabetes Obes Metab, 2025. PMID 40539310
- [3]Mechanistically resolved prediction of compound hepatotoxicity using primary human liver spheroids-Application to recent real-world cases Drug Metab Dispos, 2026. PMID 42418948
Primary literature
- PubMed: "Danuglipron"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Danuglipron"
Registered interventional and observational studies, including status and phase.
- PubChem: "Danuglipron"
Chemical structure, molecular properties, and bioactivity data.
Related peptides in Metabolic
Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed. Clinicians: join the network.